Home » Newsletters » BioWorld Science

BioWorld Science

July 2, 2007

View Archived Issues

Neogenix selects GBI to manufacture its monoclonal antibody, NPC-1C

HemispheRx initiates Ampligen phase IIb trial for seasonal flu in Australia

Promising antitumor activity of thorium-labeled rituximab

Lupulone shows antiangiogenic activity in vitro and in vivo

Preliminary phase III results for CellCept in lupus nephritis

Alnylam advances RNAi therapeutic program into IND-enabling studies

Positive phase IIa results for Speedel's renin inhibitor for hypertension

Kythera completes enrollment for phase II trial of ATX-201

Roche and Merck & Co. patents report new agents for depression, psychosis and sleep disorders

Delcath includes fourth arm to phase II study of metastatic melanoma

New diagnostic agents reported by the Universities of Pittsburgh and Hong Kong

Acadia initiates phase IIb trial of ACP-104 for schizophrenia

Wilex begins enrollment for phase II trial for pancreatic cancer

New agents for endocrine-related disorders imparted in recent patent literature

FDA grants fast track designation for HCV-796

Alnylam initiates phase II trial of ALN-RSV01 for RSV

Organon signs asset purchase agreement for Kadmus' FAAH technology

New phase III trial studies sunitinib malate in metastatic colorectal cancer

Wyeth licenses osteoporosis drug targets from Galapagos collaboration

Largest international study of patients on dialysis begins in Europe

NanoEmulsion diclofenac cream begins phase IIa study

Amendment to Lialda agreement

Schering-Plough will not enter new exclusivity period to negotiate celgosivir license

Highly immunogenic ribosomal-based vaccine protects against Shigella infection

CH-1504 begins bioequivalence study

Priority review for Taxotere sNDA in head and neck cancer

ALT-2074 begins phase II study in patients with diabetes and Hp2-2

Vyvanse filed for ADHD in adults

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...